Camostat

Camostat

SCHEMBL125269

CN(C)C(=O)COC(=O)Cc1ccc(OC(=O)c2ccc(NC(=N)N)cc2)cc1

nearest known ligand 0.68

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRSS1 P07477 5/20 0.68
KLK1 P06870 4/20 0.68
F2 P00734 2/20 0.68
TMPRSS2 O15393 2/20 0.68
SLC22A2 O15244 1/20 0.68
HPN P05981 1/20 0.68
PRSS2 P07478 1/20 0.68
CTSL P07711 1/20 0.68
CNR1 P21554 1/20 0.68
PRSS3 P35030 1/20 0.68
ADRA1A P35348 1/20 0.68
OPRD1 P41143 1/20 0.68
HGFAC Q04756 1/20 0.68
KCNH2 Q12809 1/20 0.68
SLC47A2 Q86VL8 1/20 0.68
SLC47A1 Q96FL8 1/20 0.68
KLK7 P49862 4/20 0.46
SMN1; SMN2 Q16637 4/20 0.45
NPC1 O15118 2/20 0.45
POLB P06746 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20008640 1.00 PRSS1 (0.68) PRSS1KLK1F2TMPRSS2SLC22A2
Camostat SCHEMBL2782237 0.99 PRSS1 (0.67) PRSS1KLK1F2TMPRSS2SLC22A2
Camostat SCHEMBL8829828 0.98 PRSS1 (0.66) PRSS1KLK1F2TMPRSS2SLC22A2
Camostat SCHEMBL1645380 0.97 PRSS1 (0.64) PRSS1KLK1F2TMPRSS2SLC22A2
Camostat SCHEMBL1645520 0.96 PRSS1 (0.63) PRSS1KLK1F2TMPRSS2SLC22A2
Camostat SCHEMBL871583 0.96 PRSS1 (0.72) PRSS1KLK1F2TMPRSS2SLC22A2
Camostat SCHEMBL23803656 0.95 PRSS1 (0.62) PRSS1KLK1F2TMPRSS2SLC22A2
Camostat SCHEMBL1648303 0.95 PRSS1 (0.62) PRSS1KLK1F2TMPRSS2SLC22A2
Camostat SCHEMBL1646099 0.95 PRSS1 (0.62) PRSS1KLK1F2TMPRSS2SLC22A2
Camostat SCHEMBL2326660 0.95 PRSS1 (0.62) PRSS1KLK1F2TMPRSS2SLC22A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 3914 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4228644-B1 N-[4-[1-(1,4-DIOXASPIRO[4.5]DEC-8-YL)-4-(8-OXA-3-AZABICYCLO[3.2.1]OCT-3-YL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL]PHENYL]-N'-METHYLUREA FOR USE IN THE TREATMENT OF COVID19 NANTCELL INC (US) 2026-05-27 EP claimed
US-20260139035-A1 HUMAN ANTIBODY AGAINST CORONAVIRUS VARIANTS OR ANTIGEN-BINDING FRAGMENT THEREOF NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (JP) 2026-05-21 US claimed
US-20260139860-A1 PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS CENTRE FOR DIGESTIVE DISEASES (AU) 2026-05-21 US claimed
US-20260130921-A1 TREATMENT OF VIRAL INFECTIONS WITH COMBINATION OF PIKFYVE KINASE INHIBITORS AND TMPRSS-2 INHIBITORS AcuraStem Incorporated (US) 2026-05-14 US claimed
EP-4725496-A2 N-[4-[1-(1,4-DIOXASPIRO[4.5]DEC-8-YL)-4-(8-OXA-3-AZABICYCLO[3.2.1]OCT-3-YL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL]PHENYL]-N'-METHYLUREA FOR USE IN THE TREATMENT OF COVID19 NantCell, Inc. (US) 2026-04-15 EP claimed
EP-4714452-A1 METHODS FOR TREATING SARS COV-2 INFECTIONS Gilead Sciences, Inc. (US) 2026-03-25 EP claimed
EP-4680248-A1 PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM Topelia Aust Limited (ACN 652 771 670) (AU) 2026-01-21 EP claimed
US-12527762-B2 Cocrystal comprising camostat and niclosamide, pharmaceutical composition comprising same and preparation method therefor IMDPHARM INC. (KR) 2026-01-20 US claimed
US-20260007597-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF VIRUS-INDUCED AIRWAY FIBROSIS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) 2026-01-08 US claimed
EP-4673157-A2 COMPOSITIONS FOR MODULATING GUT MICROFLORA POPULATIONS, TREATMENT OF DYSBIOSIS AND DISEASE PREVENTION, AND METHODS FOR MAKING AND USING SAME Persephone Biosciences, Inc. (US) 2026-01-07 EP claimed
EP-1178819-A2 GLUTATHIONE REDUCTASE FOR THERAPY AND PROPHYLAXIS OF AIDS Ansovini, Raffaele (IT) 2002-02-13 EP claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 CN claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000071146-A2 GLUTATHIONE REDUCTASE FOR THERAPY AND PROPHYLAXIS OF AIDS ANSOVINI RAFFAELE (IT) 2000-11-30 WO claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
EP-0893437-A1 TRYPTASE INHIBITOR AND NOVEL GUANIDINO DERIVATIVES ONO PHARMACEUTICAL CO., LTD. (JP) 1999-01-27 EP claimed
US-5811547-A Method for inducing crystalline state transition in medicinal substance NIPPON SHINYAJU CO., LTD. (JP) 1998-09-22 US claimed
US-5468727-A Methods of normalizing metabolic parameters in diabetics BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 1995-11-21 US claimed
EP-0287036-B1 NEW PHARMACEUTICAL COMPOSITIONS COMPRISING ESTERS OR AMIDES AS ACTIVE INGREDIENTS ONO PHARMACEUTICAL CO., LTD. (JP) 1991-04-10 EP claimed
US-4990537-A 6-amidinonaphth-2-yl or p-(n,n-dimethylcarbamoyl methoxy-carbonyl methyl) phenyl ester of p-guanidinobenzoic acid BANYU PHARMACEUTICAL CO., LTD. (JP) 1991-02-05 US claimed